Sickle Cell Disease

Prevention and treatment of complications, including pain crises and stroke; differences in how patients respond to treatment; improved stem cell transplant procedures; and new genetic therapies to treat and cure sickle cell disease.

Program Officers

Nancy DiFronzo, Ph.D.

HSCT and Adoptive Cell Therapy; GVHD; MDS

nancy.difronzo@nih.gov

301-435-0065

Nahed El Kassar, M.D., Ph.D.

Hematologic clinical trials; Women’s health; HSCT late effects

nahed.elkassar@nih.gov

301-435-0065

Traci Mondoro, Ph.D.

Translation; Cure Sickle Cell Initiative

mondorot@nhlbi.nih.gov

301-827-8283

Pankaj Qasba, Ph.D.

Hemoglobinopathies; genetic therapies; genomics; systems biology

pankaj.qasba@nih.gov

301-435-0070

Lis Welniak, Ph.D.

Cellular therapies; immunobiology

lis.welniak@nih.gov

301-435-0050

Funding Opportunities

View all active NHLBI funding opportunities